Last week, it was priority review for cervical cancer. This week, it's the fast track for difficult-to-treat ovarian cancer. That's the record for Roche's Avastin, which is now up for quick FDA approval of two new indications.
The FDA has zoomed in on testosterone products for the cardiovascular risks they might pose to consumers, even slapping a new warning on their official labels. Now, the agency has called a special advisory committee meeting to probe two trials that flagged an increased risk of heart attack in men using the meds.
Fresh off grossing $103.5 million in an overstuffed IPO, Cambridge, MA's Sage Therapeutics has secured the promise of a speedy FDA review for its top prospect, a treatment for a rare seizure disorder.
The FDA continues its battle with a Dallax, TX compounding pharmacy which it says is not meeting sterility standards.
The FDA has cleared Expanding Orthopedics's FLXfit implant for spinal fusion surgery, the Israeli company announced July 21.
Varian Medical Systems scored FDA 510(k) clearance for its soft tissue transponder for radiotherapy and radiosurgery treatments.
The president of the Society for Cardiovascular Angiography and founder of the Children with Diabetes Foundation made their case for faster approvals at a July 17 AdvaMed hearing in Washington, DC.
The FDA issued Paris-based AB Science a warning letter regarding its Kinavet-CA1 canine drug, intended for mast cell tumors in dogs, for allegedly boasting its off-label uses without approval.
Aduro BioTech joined the short list companies outside Big Pharma to pick up the FDA's coveted breakthrough therapy designation, impressing the agency with strong mid-stage results for its combo cancer therapy.
Former FDA associate commissioner Peter J. Pitts added his voice to calls for the need to regulate animal drug compounders who put together illegal animal drug combos, accusing the FDA of doing nothing while animals are dying from the practice.